Cereno Scientific AB (publ) (FRA:4A1)

Germany flag Germany · Delayed Price · Currency is EUR
0.715
-0.006 (-0.76%)
Last updated: Dec 5, 2025, 8:03 AM CET
38.07%
Market Cap 222.62M
Revenue (ttm) 4.22M
Net Income (ttm) -10.25M
Shares Out n/a
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 456
Open 0.715
Previous Close 0.720
Day's Range 0.715 - 0.715
52-Week Range 0.415 - 1.103
Beta n/a
RSI 56.34
Earnings Date Nov 27, 2025

About Cereno Scientific AB

Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden and internationally. The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and anti-thrombotic properties. Its drugs portfolio ... [Read more]

Industry Pharmaceutical Preparations
Founded 2012
Employees 10
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 4A1
Full Company Profile

Financial Performance

In 2024, Cereno Scientific AB's revenue was 80.90 million, an increase of 64.18% compared to the previous year's 49.28 million. Losses were -99.53 million, 106.9% more than in 2023.

Financial numbers in SEK Financial Statements

News

There is no news available yet.